Skip to NavigationSkip to content

Novartis' ligelizumab tops Xolair in chronic spontaneous urticaria

Published on 09/01/20 at 11:04am

Novartis has provided a burst of new data directly comparing its therapy ligelizumab with the current standard of care Xolair (omalizumab), also manufactured by the company, in the treatment of the skin condition chronic spontaneous urticaria (CSU).

The firm revealed that a new study determined that ligelizumab is more effective at inhibiting the major pathogenic IgE/FcεRI pathway in CSU compared to Xolair, binding to IgE in a different manner and with an 88-fold higher affinity.

“This mechanistic research study is a great step forward in understanding how different anti-IgE treatments can have qualitatively and functionally distinct inhibition profiles”, explained Dr Alexander Eggel of the University of Bern, Switzerland, and an investigator on the study.

“We were recently encouraged by previous clinical study results showing more patients are completely symptom-free from CSU with ligelizumab than Xolair,” added Eric Hughes, Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis. “This mechanistic study further supports those findings as we look to reimagine care to bring better treatment options for patients with CSU.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches